Replies to post #164819 on Biotech Values

[DewDiligence]

That's actually an increase of 1.4% QoQ; do you know if some of the increase is due to pricing?

[DewDiligence]

(MNTA/MYL/TEVA)—3Q13 US Copaxone sales reported by Teva were $798M, +3% YoY and -2% QoQ:

http://finance.yahoo.com/news/teva-reports-third-quarter-2013-122900041.html

YoY sales would have declined if not for a price increase. Still, Copaxone is holding up pretty well in the US market given the electrifying launch of BIIB’s Tecfidera (#msg-93439690).